Novel Therapeutic Agent against Platelet Activation In Vitro and Arterial Thrombosis In Vivo by Morin Hydrate
Authors:
- Chih-Wei HsiaCHChih-Wei Hsia
- Ming-Ping WuMWMing-Ping Wu
- Marappan VelusamyMVMarappan Velusamy
- Chih-Hsuan HsiaCHChih-Hsuan Hsia
- Duen-Suey ChouDCDuen-Suey Chou
- Cheng-Lin TsaiCTCheng-Lin Tsai
- Chia-Yuan HsuCHChia-Yuan Hsu
- Thanasekaran JayakumarThanasekaran Jayakumar
- Chi-Li ChungCCChi-Li Chung
- Joen-Rong SheuJoen-Rong Sheu
Open Access
- 13 August 2018
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 19 (8) , 2386
Abstract
Morin hydrate, a bioactive flavonoid, has been proven to prevent inflammation and apoptosis of cells. Flavonoids can reduce the risk of cardiovascular diseases, in which platelet activation plays a major role. This study investigated the effect of morin hydrate on platelet activation in vitro and in vivo. Morin hydrate markedly inhibited platelet aggregation stimulated by collagen in human platelets but not that stimulated by other agonists. In collagen-activated platelets, morin hydrate inhibited adenosine triphosphate (ATP) release; intracellular Ca2+ mobilization; P-selectin expression; and phosphorylation of phospholipase Cγ2 (PLCγ2), protein kinase C (PKC), and Akt. In mitogen-activated protein kinase (MAPK) activation, morin hydrate evidently diminished ERK2 or JNK1 activation, except for p38 MAPK. Additionally, morin hydrate markedly reduced the OH· signals in platelet suspensions but not in the cell-free system (Fenton reaction solution). Moreover, morin hydrate substantially increased the occlusion time of thrombotic platelet plug formation but had no effect on bleeding time in mice. In conclusion, morin hydrate crucially inhibits platelet activation through inhibition of the PLCγ2–PKC cascade and subsequent suppression of Akt and MAPK activation, thereby ultimately inhibiting platelet aggregation. Therefore, this paper suggests that morin hydrate constitutes a novel and potential natural therapeutic product for preventing or treating thromboembolic disorders.Keywords
Funding Information
- Ministry of Science and Technology, Taiwan (MOST 104-2622-B-038-003, MOST 104-2320-B-038-045-MY2, MOST 106-2320-B-038-012, MOST 107-2320-B-038-035-MY2)
- Chi-Mei Medical Center–Taipei Medical University (105CM-TMU-14)
- University Grants Commission of India (MRP-MAJOR-CHEM-2013-5144; 69/2014 F. No. 10-11/12UGC)
This publication has 35 references indexed in Scilit:
- Akt signaling in platelets and thrombosisExpert Review of Hematology, 2010
- Cellular protection of morin against the oxidative stress induced by hydrogen peroxideChemico-Biological Interactions, 2009
- The highly specific platelet glycoprotein (GP) VI agonist trowaglerix impaired collagen‐induced platelet aggregation ex vivo through matrix metalloproteinase‐dependent GPVI sheddingJournal of Thrombosis and Haemostasis, 2008
- Roles of the C-terminal tyrosine residues of LAT in GPVI-induced platelet activation: insights into the mechanism of PLCγ2 activationBlood, 2007
- Protective Mechanisms of Inosine in Platelet Activation and Cerebral Ischemic DamageArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- ESR spin trapping of a carbon-centered free radical from agonist-stimulated human plateletsFree Radical Biology and Medicine, 2005
- Aggretin, a snake venom–derived endothelial integrin α2β1 agonist, induces angiogenesis via expression of vascular endothelial growth factorBlood, 2004
- A role for p38 MAP kinase in platelet activation by von Willebrand FactorThrombosis and Haemostasis, 2004
- Convulxin Binding to Platelet Receptor GPVI: Competition with Collagen Related PeptidesBiochemical and Biophysical Research Communications, 2000
- Roles of PLC-β2 and -β3 and PI3Kγ in Chemoattractant-Mediated Signal TransductionScience, 2000